The protective effects of dexmedetomidine (DEX) mediated by reductions of oxidative stress, mitochondrial damage and disintegration have been demonstrated in many injury models. However, whether DEX has a beneficial effect on traumatic brain injury (TBI) remains unknown. In this study, the neuroprotective effect of DEX and its potential mechanism were assessed in a model of TBI. DEX treatment relieved encephala edema and neuron cell apoptosis and increased behavioral function. These protective effects were accompanied by upregulation of peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1α) expression. These findings imply that DEX protects neurons following TBI, possibly by activating the PGC-1α pathway. The data will help clarify the mechanisms responsible for the anti-apoptosis effect of DEX with possible involvement of the PGC-1α pathway.
Introduction
Traumatic brain injury (TBI) is a fatal neurological injury that is a major public health problem worldwide. TBI leads to high medical costs, morbidity and mortality (Terry et al., 2018; Sabella et al., 2018) . Following primary mechanical injury of brain cells, secondary brain damage triggers a complex pathological process that may eventually result in a series of deleterious side effects that include oxidative stress, free radical production and inflammatory response, which can lead to further neuronal degeneration and apoptosis. These subsequent pathological events are referred to as secondary brain injury (Liang et al., 2018; Jassam et al., 2017) . Although many basic and clinical research studies of TBI have been done, no cure has emerged. An effective method for TBI patients is needed.
The peroxisome proliferator-activated receptor gamma (PPAR-γ) coactivator-1 (PGC-1α) family of related transcription factors functions as a "transfer station" in many metabolic activities (Liu et al., 2017) . PGC-1α plays a key role in different neurological disorders. For example, it has been reported to be changed in the brain of Parkinson's and Alzheimer's patients (Rasouri et al., 2007; Robinson et al., 2014) . In addition, it is one of most important factors in the upregulation of the antioxidant pathway (Bouitbir et al., 2012) . PGC-1α is generally recognized a mediator of gene regulation involved in the reactive oxygen species (ROS) defense system (Lu et al., 2010) . Increased expression of PGC-1α and mRNA are detected in the neurons following TBI (Fan et al., 2012) . Nevertheless, PGC-1α may have a key role in the brain following TBI.
Dexmedetomidine (DEX) is a central adrenoceptor α-2A agonist that is widely used as a sedative and for analgesia and sympatholytic properties (Di et al., 2017) . DEX attenuates ischemia-reperfusion and ventilator-induced lung injury Hu et al., 2017) . Additionally, DEX suppresses systemic inflammation and oxidative stress, suggesting that it has anti-inflammatory and anti-apoptotic effects. Many researches demonstrated that the recovery of brain damage can be promoted by DEX administration in animal models of ischemia/reperfusion, excitotoxicity and synaptic degeneration Shen et al., 2017) . Recently, some signaling pathways have been proven to play a crucial role in the treatment of TBI, such as the factor-β1/nuclear factor-κB and Akt/GSK-3beta/beta-catenin signaling pathways (Zhao et al., 2012; Zhang et al., 2017a) . However, there has been a paucity of investigation into the neuroprotective effects of DEX in TBI models.
The purpose of the study was to investigate the neuroprotective effects and potential mechanisms of DEX, and to explore whether DEX can regulate the PGC-1α signaling pathway after TBI. Also, the efficacy of the protective effects of DEX against injuries in various organs was established (Meng et al., 2018) . In addition, the neuroprotective effect of DEX and the PGC-1α pathway activation drew our attention.
Materials and methods

Animals
Male Sprague-Dawley (SD) rats weighing 250-280 g were obtained from the Experiment Animal Center of Nanjin Medical University. The animals were fed at a temperature of 24 ± 0.5°C with random food and water intake for 3 days before the experiment. The protocols were ratified by the Animal Care and Use Committee at the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University and conformed to the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health (Bethesda, MD, USA).
Model of TBI
The weight-drop TBI model was used as previous study (Flierl et al., 2009) .. Rats were placed on a stereotaxic frame after being anesthetized using 10% chloral hydrate (250 mg/kg). A 1.5 cm midline scalp incision was made and the skull was exposed. A 6-mm hole was made on the left anterior frontal area, with care taken to maintain the dura must intact during the operation. A 40-g weight was released onto the dura from a height of 2.5 cm. The scalp wound was sutured and the rats were returned to their former cages. Sham animals underwent the same procedures except for the exclusion of the weight drop.
Experimental design
The first experiment involved 41 rats. Five died post-operatively and were excluded. The remaining 36 rats post-TBI were divided into six groups (n = 6 per group)-Sham, TBI, TBI + vehicle, TBI + DEX (20 μg/kg), TBI + DEX (50 μg/kg), and TBI + DEX (100 μg/kg).] and killed at 1d after TBI for brain water content. (n = 6 each). And then, 6 rats were elected for neurological evaluation at 1d, 3d and 7 d following TBI.
The second experiment was done to determine the role of PGC-1α after TBI. The experiment involved 87 rats (15 rats died) were divided into four groups (n = 18 each): Sham group; TBI group; TBI+ vehicle group; TBI+ DEX group. All the rats were killed 24 h following TBI for evaluations (n = 6 for each evaluation) that included western blot, staining of nucleic acid (Nissl staining), immunohistochemical staining, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, malondialdehyde (MDA) assay, and glutathione peroxidase (GPx) assay.
Rats in the TBI + DEX group, were injected intraperitoneally with DEX (Xincheng, Jiangsu, China) dissolved in saline as a 1 μg/μL solution, 30 min after TBI. Rats in the TBI + vehicle group received equal volumes of the vehicle solution at the same time point.
Tissue processing
For western blot analysis, animals were rapidly killed 24 h post-TBI and their ipsilateral cortexes were collected. The tissue was positioned directly over the center of the injury site and included both contusions and penumbra. Samples were immediately frozen in liquid nitrogen and stored at −80°C until use. For immunohistochemistry analysis, Nissl staining, and TUNEL assay, the whole brain was removed 24 h after TBI and immersed in 4% paraformaldehyde overnight.
Brain water content
Brain water content was measured at 24 h after TBI. Animals were sacrificed and the brain left cortical tissue was collected. The tissue was separated over the injury site, covering the cerebrum, cerebellum, and brain stem. The fresh tissue was weighed immediately (wet weight) and then dried at 80°C for 72 h (dry weight). The brain water content (%) was calculated as: [(wet weight − dry weight)/wet weight] × 100%.
Neurological evaluation
The neurologic status of rats was evaluated by the beam-walking test. The investigators perform seven different tasks that analyzed motor function, balance, and other aspects. Briefly, beam-walking performance was rated using a seven point rating scale, as follows: 1, the animal is unable to place theaffected hind limb on the horizontal surface of the beam; 2, the animal places the affected hind limb on the horizontal surface of the beam and maintains balance but is unable to traverse the beam; 3, the animal traverses the beam dragging the affected hind limb; 4, the animal traverses the beam while on one occasion placing the affected hind limb on the horizontal surface of the beam; 5, the animal crosses the beam while placing the affected hind limb on the horizontal surface of the beam to aid fewer than half of its steps;6, the animal uses the affected hind limb to aid more than half of its steps; and 7, the animal traverses the beam with no more than two foot slips. One point was scored for the failure of a task (i.e., falling off the beam). The scores ranged from 0 (minimum deficit) to 7 (maximum deficit). The test was recorded by two independent observers who were blind to the experiment protocol.
Nissl staining
Paraffin-embedded sections of the cerebral cortex were stained with cresyl violet as previously described . Normal neurons displayed large cell bodies and round nuclei, and were enriched in cytoplasm. In contrast, damaged cells were shrunken with condensed and hyperchromatic nuclei, and dark cytoplasm containing vesicles. Six fields (400×) in each section were observed and the mean number in the six views was regarded as the data of each section.
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling(TUNEL) analysis
Dying cells were detected by TUNEL detection kit (Roche, South San Francisco, CA, USA) as per the manufacturer's instructions and as previously described (Shen et al., 2017) . Apoptotic cells exhibited cellular atrophy with cataplasia nuclei stained brown. These cells were enumerated by an observer who was blind to the experiment. The extent of brain damage was evaluated by the apoptotic index in six microscopic fields (400×). The final percentage of the positive cells of the six sections was the data for each tissue.
Western blot analysis
Protein extraction was performed by the well-established Bradford method. Equal amounts of protein were resolved by 10% or 12% SDS-PAGE and the resolved proteins transferred to polyvinylidene fluoride membranes. The membranes were blocked for 2 h in 5% skimmed milk in Tris buffered saline containing Tween 20 (TBST) at 37°C and incubated at 4°C with PGC-1α (1:1000, Millipore, Billerica, MA, USA), H3 (1:1000, Cell Signaling Technology, Danvers, MA, USA), cleaved caspase-3 (1:1000, Cell Signaling Technology, Danvers, MA, USA), Bax (1:400, Abcam, Cambridge, MA, USA), Bcl-2 (1:1000, Cell Signaling Technology, Danvers, MA, USA), and β-actin (1:5000, Bioworld Technology, Saint Louis Park, MN, USA) in blocking buffer. Then, the membranes were washed with TBST for 15 min and incubated with goat secondary antibodies (1:5000; Bioworld Technology) for 2 h. After washing with TBST three times for 5 min each wash, the protein bands were visualized by ECL (Millipore, Billerica, MA, USA) and exposure to X-ray film.
Immunohistochemical staining
Brain tissue samples were fixed in formalin for 24 h and embedded in paraffin. Sections were cut at a thickness of 4 μm and deparaffinized
Neuropeptides xxx (xxxx) xxx-xxx in xylene, dehydrated in a graded series of ethanol, subjected to antigen retrieval in citrate buffer (pH 6.0) for 30 min in a 37°C chamber, and washed in phosphate buffered saline (PBS). The sections were quenched in 3% horseradish peroxidase (HRP)-conjugated rabbit IgG (1:400; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at 37°C then incubated with rabbit monoclonal anti-PGC-1α antibody (1:300; Abcam, Cambridge, MA, USA) overnight at 4°C, followed by three 15-min washes in PBS and incubation with HRP-conjugated IgG (1:500; Bioworld Technology) for 60 min at room temperature. After washing in PBS three times, immunolabeled protein was stained brown after staining with diaminobenzidine and hematoxylin counterstaining. Six fields selected randomly in each section were observed and the number of positive neurons in selected fields was recorded.
Malondialdehyde (MDA) content, Superoxide Dismutase (SOD) and glutathione peroxidase (GPx) activity
The level of MDA content (nmol/mg),SOD and GPx activity (U/mg protein) were measured using a spectrophotometer (Nanjing Jiancheng Biochemistry Co, Nanjing, China) following the manufacturer's instructions.
Statistical analyses
Data are reported as the mean ± SEM and evaluated by ANOVA followed by Tukey's post hoc test. SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used for the analyses. Statistical significance difference was inferred at p < .05.
Results
DEX alleviates cerebral edema following TBI
The brain water content was significantly increased in the TBI and TBI + vehicle groups (Fig. 1) . Brain water content of rats treated with DEX (50, 100 μg/kg) was significantly less than that of the TBI + vehicle group, but the dose of 100 μg/kg failed to further improve the effect compared to 50 μg/kg. Thus, 50 μg/kg was selected as the dose in the following experiments.
One day of TBI, worse neurological function was evident in the TBI + vehicle group than in the TBI + 50 and TBI + 100 μg/kg groups (p < .05) (Fig. 1B) . After DEX treatment, the neurological score was significantly improved than the TBI + vehicle group (p < .05), with the dose of 50 and 100 μg/kg producing the same effect.
DEX reduces neuronal degeneration
Only a few apoptotic positive cells were detected in the sham group. Compared with the sham group, the apoptotic index in the TBI + vehicle group was obviously increased ( Fig. 2A and C) . The apoptotic index did not differ in the TBI group and the TBI+ vehicle group, but a decrease was observed in the TBI + DEX group (Fig. 2B-D) .
Only a few TUNEL-positive cells were detected in the cerebral cortex of rats in the sham group (Fig. 2E) . Compared with the sham group, the percentage of TUNEL-positive cells was markedly greater in the TBI + vehicle group (Fig. 2G, E) but was reduced in the TBI + DEX group (Fig. 2H) .
DEX enhances PGC-1α expression
Comparisons of the expressions of nuclear, cytoplasm, and total PGC-1α protein revealed that both the TBI and DEX treatment promoted PGC-1α nuclear translocation (Fig. 3A , B, D, and E). In addition, compared to the vehicle treated group, the DEX-treated group had a significantly increased ratio of nuclear and cytoplasmic PGC-1α (Fig. 3C, D and E-J). However, DEX treatment could provide further promotion of this transformation.
Expression of cleaved caspase-3 is reduced by DEX
The percentage of cells that were positive for cleaved caspase-3 in the TBI+ DEX group was lower than in the TBI+ vehicle group. Cleaved caspase-3 expression in the cortex was elevated 24 h after TBI (Fig. 4A, C) . Compared with the sham group, the level of Bcl-2 protein was increased, whereas the level in the cytosol was decreased significantly (Fig. 4A, B) .
3.2 DEX reduces oxidative stress markers following TBI
Compared with the sham group, the level of MDA was increased in the TBI + vehicle group (Fig. 5A ). This variation was eliminated by the administration of DEX (Fig. 5A ). GPx and SOD is an antioxidant enzyme responsible for scavenging metabolites generated by oxidative stress. Fig. 1 . Administration of DEX protects rats against secondary brain injury after TBI (A,B). Rats were subjected to TBI and then received 20, 50, and 100 μg/kg of DEX or vehicle 30 min after TBI. Beam-walking test score was evaluated at 1, 3, and 7 d after TBI while brain water content was examined at 1 d after TBI. (A) Rats subjected to TBI or treated with vehicle had upregulation brain water content as compared with the sham group. Brain water content was significantly lower in rats who received DEX (20, 50, 100 μg/kg) compared with the vehicle treated group (n = 6). (B) The 50 and 100 μg/kg groups displayed improved motor performance within 1 d. However, there was no significant difference between the 20 μg/kg group and the vehicle group. This effect was no longer significant 7 d after TBI in all groups treated with different doses of DEX and the vehicle treated group (n = 6). Data are presented as mean ± SEM, ***p < .001 vs sham group; #p < .05 vs TBI + vehicle group.
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GPx and SOD activity was reduced following TBI ( Fig. 5B ) but treatment with 50 μg/kg DEX increased GPx and SOD activity .
Discussion
There are presently no effective strategies for mitigating brain damage caused by trauma, while the molecular basis for TBI-induced neurodegeneration remains obscure. Secondary brain injury after TBI represents a type of chain reaction that involves, oxidative stress, loss of Ca 2+ homeostasis, inflammatory response, and other factors Kokiko-Cochran and Godbout, 2018) . Oxidative stress is a key factor in the pathophysiology of TBI and regulates the subsequent histopathology and neurological function deficits (Dobrovolny et al., 2018; Szarka et al., 2018 ). The ever-increasing level of ROS through various cellular pathways plays an important role in TBI (Angeloni et al., 2015) . ROS can cause lipid peroxidation, protein oxidation, and DNA damage (Butterfield and Reed, 2016; Slemmer et al., 2008) . Thus, a beneficial neuroprotective agent must limit and reverse oxidative stress. The MDA level reflects the index of lipid peroxidation, and begins to increase immediately after TBI. Meanwhile, the intracellular antioxidant enzyme, SOD and GPx, scavenges metabolites generated by free radicals, converting lipid peroxides and hydrogen peroxide into nontoxic compounds (Xu et al., 2014) . In the present study, the content of MDA and the level of activity of SOD and GPx in neuron cells in the cortical region following TBI indicated that oxidative stress had occurred. Additionally, DEX treatment after TBI reduced the MDA content and increased the level of SOD and GPx activity, suggesting that DEX can protect neuron cells by restraining oxidative stress.
One of the effects of DEX is presynaptic inhibition of the release of noradrenaline and cell firing in the brain (Zhang et al., 2017b) . Previous studies showed that DEX improves neuronal survival in excitotoxic lesions and has neuroprotective effects by inhibiting inflammation (Zhang et al., 2018) . Thus, the aim of this study was demonstrating histological evidence of neuroprotection while using DEX. This investigation would pave the way to future trials investigating DEX as an sedation in TBI patient. The results of Nissl staining and TUNEL showed that treatment with 50 μg/kg DEX reduced neuronal cell apoptotic in the cortex after TBI. The mechanism of how DEX exerts a neuroprotective effect on TBI remains unknown. Recent evidence suggests that this effect is mediated not only by the alpha-2 agonistic properties of Dex, but also by its binding to imidazoline I1-receptors (Dahmani et al., 2008) . Since DEX is a highly selective agonist of adrenoceptor α-2A, its neuroprotective effect may be neuronal adrenoceptor α2A-dependent (Castillo et al., 2017) . In this study, treatment with DEX (50 μg/kg) enervated the contusion-induced brain edema and alleviated neuronal apoptosis. Also, DEX treatment stimulated the activation of the PGC-1α pathway. The present study is the first to evaluate the effects of DEX in neuroprotection via the PGC-1α signaling pathway in a rat model of TBI.
PGC-1α is a multi-functional protein that plays an important role in many nervous system diseases (Yu et al., 2017) . The level of nuclear PGC-1α is significantly increased after TBI (Li et al., 2016) . To confirm the relevant role of the PGC-1α pathway in the neuroprotection of the injured cortex, the level of PGC-1α protein expression was determined after the administration of DEX. The results confirmed that the PGC-1α protein moved from the cytoplasm to the nucleus following TBI, and Fig. 4 . Effect of DEX on cleaved caspase-3 and Bcl-2 expression in cortical neural cells in the rat model of TBI as assessed by western blot (A-C, n = 6). Expression was normalized to the level of β-actin. Data are presented as mean ± SEM. **p < .01, ***p < .001 vs. sham group, #p < .05, ##p < .05 vs. TBI + vehicle group. that DEX accelerated this translocation. These results imply that the expression of PGC-1α was upregulated and DEX induced its variation in the rat model of TBI. Except that, expression of PGC-1α signaling pathway-related proteins was increasing the TBI groups compared with the control group, suggesting that TBI inhibited the activation of the PGC-1α signaling pathway. Over-expressed PGC-1α was found in the TBI + DEX group, suggesting that DEX activated the activity of PGC-1α signaling pathway.
In summary, this study verified that PGC-1α has a vital role in the neuroprotection of rats after TBI. DEX administration directly leads to the upregulation of PGC-1α protein expression in the regions with TBI. The observed change in the PGC-1α levels affirmed that PGC-1α may respond to an alteration in noradrenaline release and cell firing following TBI. Additional research should be conducted to further explore the relationship between the PGC-1α pathway and other protective, anti-apoptotic mechanisms in response to DEX treatment.
